The Food and Drug Administration (FDA) has granted accelerated approval and Priority Review to Blincyto (blinatumomab; Amgen) for the treatment of patients with B-cell precursor acute lymphoblastic leukemia (ALL) who are in remission but still have minimal residual disease (MRD). Patients in remission with MRD presence may have a higher risk of relapse. 

The accelerated approval marks Blincyto, a bispecific CD19-directed CD3 T-cell engager, as the first approved treatment for patients with MRD-positive ALL. It is already approved to treat relapsed or refractory B-cell precursor ALL. Additional data from randomized controlled trials are needed to confirm that achieving undetectable MRD with Blincyto improves survival or disease-free survival in patients with ALL. 

A single-arm trial (N=86) evaluated Blincyto in ALL patients in first or second complete remission with detectable MRD in at least 1 of 1,000 cells in their bone marrow. Efficacy was measured according to achievement of undetectable MRD in an assay that could detect at least 1 cancer cell in 10,000 cells following 1 cycle of Blincyto; hematological relapse-free survival was also measured. The data showed 70 patients achieved undetectable MRD and more than 50% survived in remission for at least 22.3 months.

Related Articles

Common adverse effects include infections, pyrexia, headache, infusion related reactions, neutopenia, anemia, febrile neutropenia, and thrombocytopenia.


Continue Reading

Blincyto is available as a 35mcg strength lyophilized powder for intravenous (IV) infusion after reconstitution.

For more information call (800) 772-6436 or visit FDA.gov.